Also trades as: 0H7R.L (LSE) · $vol 0M
ABEO NASDAQ
Abeona Therapeutics Inc.
1W: -6.8%
1M: -15.5%
3M: -20.3%
YTD: -5.3%
1Y: -4.7%
3Y: +27.0%
5Y: -83.0%
$5.03
+0.02 (+0.40%)
Weekly Expected Move ±5.6%
$4
$5
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships8
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-11-15
Earliest Filing
2025-07-18
Latest Filing
customer: 6
partner: 2
Counterparties (Filed by ABEO)
8 relationshipsCompanies named in ABEO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Abeona Therapeutics, Inc. | ABEO | customer | Primary borrower in the loan and security agreement amendment. | 2025-07-18 | View |
| MacroChem Corporation | — | customer | Co-borrower in the loan and security agreement amendment. | 2025-07-18 | View |
| Abeona Therapeutics LLC | ABEO | customer | Co-borrower (LLC) in the loan and security agreement amendment. | 2025-07-18 | View |
| ABEONA THERAPEUTICS INC. | ABEO | customer | Primary borrower in the loan agreement | 2024-01-08 | View |
| MACROCHEM CORPORATION | — | customer | Co-borrower in the loan agreement | 2024-01-08 | View |
| ABEONA THERAPEUTICS LLC | ABEO | customer | Co-borrower in the loan agreement | 2024-01-08 | View |
| Jefferies LLC | JEF | partner | Agent for the Open Market Sale Agreement | 2021-11-19 | View |
| REGENXBIO Inc. | RGNX | partner | Settlement Agreement and Mutual Release to resolve arbitrations and related proceedings arising from a terminated Licens | 2021-11-15 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ABEO in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-15 | Regulation FD; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Officer/Director Change | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-06-10 | Regulation FD; Exhibits | View | |
| 2026-06-04 | Other Events | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-04-07 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-18 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-07-02 | Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; O | Acquisition | View |
| 2025-05-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-12 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-04-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-04-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-03-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR